PHARMACOMETRIC ANALYSIS SUPPORTS EARLY ONSET OF PROTECTION WITH GARADACIMAB AGAINST HEREDITARY ANGIOEDEMA ATTACKS

被引：0
|
作者：
Glassman, F.
Sharma, A.
Garcia, R.
Lawo, J.
Nenci, C.
Pragst, I.
Polhamus, D.
Puchalski, T.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2024年 / 133卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
R096
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [1] Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks
    Staubach, Petra
    Tachdjian, Raffi
    Li, H. Henry
    Hakl, Roman
    Aygoeren-Puersuen, Emel
    Wieman, Lolis
    Lawo, John-Philip
    Craig, Timothy J.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2024,
  • [2] POPULATION EXPOSURE-RESPONSE ANALYSIS SUPPORTS EFFICACY OUTCOMES OF GARADACIMAB IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Sharma, A.
    Glassman, F.
    Garcia, R.
    French, J.
    Wiens, M.
    Miguel-Lillo, B.
    Lawo, J.
    Jacobs, I.
    Polhamus, D.
    Nandy, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S95 - S95
  • [3] Garadacimab protects against hereditary angioedema attacks from Week 1 in pivotal Phase 3 VANGUARD study
    Aygoeren-Puersuen, E.
    Tachdjian, R.
    Li, H.
    Hsu, C.
    Hakl, R.
    Staubach, P.
    Wieman, L.
    Lawo, J. -P.
    Keith, P. K.
    ALLERGOLOGIE, 2024, 47 (09)
  • [4] GARADACIMAB PROTECTS AGAINST HEREDITARY ANGIOEDEMA ATTACKS FROM WEEK 1 IN PIVOTAL PHASE 3 VANGUARD STUDY
    Tachdjian, R.
    Li, H.
    Hsu, C.
    Hakl, R.
    Staubach, P.
    Wieman, L.
    Lawo, J.
    Keith, P.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S27 - S28
  • [5] Population Pharmacokinetic/Pharmacodynamic Analysis Of Garadacimab, In Patients With Hereditary Angioedema
    Glassman, Fiona
    Sharma, Ankur
    Cheng, Shen
    Johnston, Curtis
    De Miguel Lillo, Bernardo
    Lawo, John-Philip
    Jacobs, Iris
    Polhamus, Daniel
    Nandy, Partha
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB4 - AB4
  • [6] Hereditary Angioedema: new Option for Long-term Protection against Attacks
    Kempe, Sabrina
    ALLERGO JOURNAL, 2025, 34 (01) : 12 - 14
  • [7] Benefits of Early Administration with Icatibant for the Treatment of Hereditary Angioedema Attacks
    Longhurst, Hilary
    Aberer, Werner
    Bouillet, Laurence
    Caballero, Teresa
    Fabien, Vincent
    Kanny, Gisele
    Zanichelli, Andrea
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (02) : AB33 - AB33
  • [8] The goal of prophylaxis against hereditary angioedema attacks is no attacks: a summary of findings for approved and investigational products
    Aygoeren-Puersuen, E.
    Farkas, H.
    Moldovan, D.
    Martinez-Saguer, I
    Hao, J.
    Lu, P.
    Schranz, J.
    ALLERGY, 2017, 72 : 596 - 596
  • [9] Analysis of hereditary angioedema attacks requiring a second dose of ecallantide
    Li, H. Henry
    Campion, Marilyn
    Craig, Timothy J.
    Soteres, Daniel F.
    Riedl, Marc
    Lumry, William R.
    MacGinnitie, Andrew J.
    Shea, Elizabeth P.
    Bernstein, Jonathan A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 110 (03) : 168 - 172
  • [10] Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study
    Reshef, Avner
    Hsu, Connie
    Katelaris, Constance H.
    Li, Philip H.
    Magerl, Markus
    Yamagami, Keiko
    Guilarte, Mar
    Keith, Paul K.
    Bernstein, Jonathan A.
    Lawo, John-Philip
    Shetty, Harsha
    Pollen, Maressa
    Wieman, Lolis
    Craig, Tim J.
    ALLERGY, 2025, 80 (02) : 545 - 556
12345